Trevi Therapeutics, Inc. TRVI Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $19.41M+2.6% | $18.91M-66.7% | $56.87M-51.4% | $117.06M+504% | $19.37M-43.2% | ||
| $152.37M-10.0% | $169.35M+22.7% | $138.06M+59.0% | $86.83M+3.5% | $83.88M+14.1% | ||
| $176.12M-8.1% | $191.66M-3.3% | $198.3M-4.3% | $207.23M+96.2% | $105.62M-3.5% | ||
| $265K+48.9% | $178K-16.4% | $213K-10.9% | $239K-13.7% | $277K+76.4% | ||
| $179.61M-7.2% | $193.44M-3.0% | $199.36M-4.3% | $208.34M+94.7% | $107M-3.5% | ||
| $2.22M-43.4% | $3.91M+44.4% | $2.71M-8.9% | $2.97M+109% | $1.42M-58.4% | ||
| $7.12M-27.0% | $9.75M+7.8% | $9.04M-2.2% | $9.24M+34.6% | $6.87M-34.7% | ||
| $7.48M-26.6% | $10.2M+6.6% | $9.57M-2.8% | $9.85M+30.5% | $7.55M-33.0% | ||
| $128K0.0% | $128K0.0% | $128K+4.9% | $122K+22.0% | $100K+6.4% | ||
| -$343M-4.0% | -$329.8M-2.6% | -$321.49M-3.8% | -$309.69M-4.1% | -$297.39M-3.6% | ||
| $172.13M-6.1% | $183.24M-3.4% | $189.79M-4.4% | $198.49M+99.6% | $99.46M-0.2% | ||
| $179.61M-7.2% | $193.44M-3.0% | $199.36M-4.3% | $208.34M+94.7% | $107M-3.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Trevi Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 24.75 — current assets exceed current liabilities.
- Where does Trevi Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Trevi Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.